The influence of metallo-β-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections
暂无分享,去创建一个
L. Goldani | A. Zavascki | A. F. Martins | A. Barth | A. Gonçalves | F. Ramos | A. L. Moro | J. Fernandes
[1] A. Peleg,et al. Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] A. Zavascki,et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing SPM-1 metallo-{beta}-lactamase in a teaching hospital in southern Brazil. , 2005, The Journal of antimicrobial chemotherapy.
[3] G. Rossolini,et al. Novel Acquired Metallo-β-Lactamase Gene, blaSIM-1, in a Class 1 Integron from Acinetobacter baumannii Clinical Isolates from Korea , 2005, Antimicrobial Agents and Chemotherapy.
[4] D. Church,et al. Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains. , 2005, The Journal of infectious diseases.
[5] Timothy R. Walsh,et al. Metallo-β-Lactamases: the Quiet before the Storm? , 2005, Clinical Microbiology Reviews.
[6] M. Kaufmann,et al. Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa Producing VIM-8, a Novel Metallo-β-Lactamase, in a Tertiary Care Center in Cali, Colombia , 2004, Journal of Clinical Microbiology.
[7] Yasuaki Yamada,et al. Clinical and bacteriological characteristics of IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] D. Livermore,et al. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] H. Giamarellou. Prescribing guidelines for severe Pseudomonas infections. , 2002, The Journal of antimicrobial chemotherapy.
[10] Richard A. Moore,et al. Nosocomial Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa with a New blaIMP Allele, blaIMP-7 , 2002, Antimicrobial Agents and Chemotherapy.
[11] Ronald N. Jones,et al. Contemporary Assessment of Antimicrobial Susceptibility Testing Methods for Polymyxin B and Colistin: Review of Available Interpretative Criteria and Quality Control Guidelines , 2001, Journal of Clinical Microbiology.
[12] Y. Arakawa,et al. Convenient Test for Screening Metallo-β-Lactamase-Producing Gram-Negative Bacteria by Using Thiol Compounds , 2000, Journal of Clinical Microbiology.
[13] S. Huttly,et al. The role of conceptual frameworks in epidemiological analysis: a hierarchical approach. , 1997, International journal of epidemiology.
[14] D H Persing,et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.
[15] J. Concato,et al. The Risk of Determining Risk with Multivariable Models , 1993, Annals of Internal Medicine.
[16] W. Knaus,et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.
[17] B. Yangco,et al. CDC definitions for nosocomial infections. , 1989, American journal of infection control.
[18] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.
[19] M. Kaufmann,et al. Pulsed-field gel electrophoresis. , 1998, Methods in molecular medicine.
[20] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.